Modeling Heartland virus disease in mice and therapeutic intervention with 4'-fluorouridine
Heartland virus (HRTV) is an emerging tick-borne bandavirus that causes a febrile illness of varying severity in humans, with cases reported in eastern and midwestern regions of the United States. No vaccines or approved therapies are available to prevent or treat HRTV disease. Here, we describe the genetic changes, natural history of disease, and pathogenesis of a mouse-adapted HRTV (MA-HRTV) that is uniformly lethal in 7- to 8-week-old AG129 mice at low challenge doses. We used this model to assess the efficacy of the ribonucleoside analog, 4'-fluorouridine (EIDD-2749), and showed that once-daily oral treatment with 3 mg/kg of drug, initiated after the onset of disease, protects mice against lethal MA-HRTV challenge and reduces viral loads in blood and tissues. Our findings provide insights into HRTV virulence and pathogenesis and support further development of EIDD-2749 as a therapeutic intervention for HRTV disease.
IMPORTANCE: More than 60 cases of HRTV disease spanning 14 states have been reported to the United States Centers for Disease Control and Prevention. The expanding range of the Lone Star tick that transmits HRTV, the growing population of at-risk persons living in geographic areas where the tick is abundant, and the lack of antiviral treatments or vaccines raise significant public health concerns. Here, we report the development of a new small-animal model of lethal HRTV disease to gain insight into HRTV pathogenesis and the application of this model for the preclinical development of a promising new antiviral drug candidate, EIDD-2749. Our findings shed light on how the virus causes disease and support the continued development of EIDD-2749 as a therapeutic for severe cases of HRTV infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Journal of virology - 98(2024), 4 vom: 16. Apr., Seite e0013224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Westover, Jonna B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4'-fluorouridine |
|---|
| Anmerkungen: |
Date Completed 17.04.2024 Date Revised 18.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/jvi.00132-24 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370015177 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370015177 | ||
| 003 | DE-627 | ||
| 005 | 20240418232820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/jvi.00132-24 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM370015177 | ||
| 035 | |a (NLM)38511932 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Westover, Jonna B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modeling Heartland virus disease in mice and therapeutic intervention with 4'-fluorouridine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2024 | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Heartland virus (HRTV) is an emerging tick-borne bandavirus that causes a febrile illness of varying severity in humans, with cases reported in eastern and midwestern regions of the United States. No vaccines or approved therapies are available to prevent or treat HRTV disease. Here, we describe the genetic changes, natural history of disease, and pathogenesis of a mouse-adapted HRTV (MA-HRTV) that is uniformly lethal in 7- to 8-week-old AG129 mice at low challenge doses. We used this model to assess the efficacy of the ribonucleoside analog, 4'-fluorouridine (EIDD-2749), and showed that once-daily oral treatment with 3 mg/kg of drug, initiated after the onset of disease, protects mice against lethal MA-HRTV challenge and reduces viral loads in blood and tissues. Our findings provide insights into HRTV virulence and pathogenesis and support further development of EIDD-2749 as a therapeutic intervention for HRTV disease | ||
| 520 | |a IMPORTANCE: More than 60 cases of HRTV disease spanning 14 states have been reported to the United States Centers for Disease Control and Prevention. The expanding range of the Lone Star tick that transmits HRTV, the growing population of at-risk persons living in geographic areas where the tick is abundant, and the lack of antiviral treatments or vaccines raise significant public health concerns. Here, we report the development of a new small-animal model of lethal HRTV disease to gain insight into HRTV pathogenesis and the application of this model for the preclinical development of a promising new antiviral drug candidate, EIDD-2749. Our findings shed light on how the virus causes disease and support the continued development of EIDD-2749 as a therapeutic for severe cases of HRTV infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Heartland bandavirus | |
| 650 | 4 | |a Heartland virus | |
| 650 | 4 | |a animal models | |
| 650 | 4 | |a antiviral agents | |
| 650 | 4 | |a bandavirus | |
| 650 | 4 | |a molecular genetics | |
| 650 | 4 | |a virulence determinants | |
| 650 | 7 | |a 4'-fluorouridine |2 NLM | |
| 650 | 7 | |a Uracil Nucleotides |2 NLM | |
| 700 | 1 | |a Jung, Kie Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Alkan, Cigdem |e verfasserin |4 aut | |
| 700 | 1 | |a Boardman, Kirsten M |e verfasserin |4 aut | |
| 700 | 1 | |a Van Wettere, Arnaud J |e verfasserin |4 aut | |
| 700 | 1 | |a Martens, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas, Inioska |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Aaron J |e verfasserin |4 aut | |
| 700 | 1 | |a Saindane, Manohar T |e verfasserin |4 aut | |
| 700 | 1 | |a Bluemling, Gregory R |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Shuli |e verfasserin |4 aut | |
| 700 | 1 | |a Kolykhalov, Alexander A |e verfasserin |4 aut | |
| 700 | 1 | |a Natchus, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Bates, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Painter, George R |e verfasserin |4 aut | |
| 700 | 1 | |a Ikegami, Tetsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Gowen, Brian B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of virology |d 1967 |g 98(2024), 4 vom: 16. Apr., Seite e0013224 |w (DE-627)NLM000006866 |x 1098-5514 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2024 |g number:4 |g day:16 |g month:04 |g pages:e0013224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/jvi.00132-24 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2024 |e 4 |b 16 |c 04 |h e0013224 | ||